Multi-Hospital Eastern Atlantic Restenosis Trial. II: A placebo-controlled trial of thromboxane blockade in the prevention of restenosis following coronary angioplasty

Am Heart J. 1991 Nov;122(5):1239-44. doi: 10.1016/0002-8703(91)90561-u.


Since platelet interactions appear to play an important role in the development of restenosis, attenuation of thromboxane-mediated reactions may improve the long-term outcome following coronary angioplasty. Phase II of the Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART) is a prospective, randomized, placebo-controlled study of thromboxane blockade in the prevention of restenosis following successful coronary angioplasty. Two forms of thromboxane blockade are evaluated: aspirin (a nonspecific inhibitor of thromboxane synthesis) and sulotroban (a specific thromboxane receptor antagonist). The design of this multicenter trial and the rationale for use of sulotroban in the prevention of restenosis are reviewed in this report.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angioplasty, Balloon, Coronary*
  • Aspirin / therapeutic use
  • Coronary Angiography
  • Coronary Disease / diagnostic imaging
  • Coronary Disease / epidemiology
  • Coronary Disease / prevention & control*
  • Coronary Disease / therapy
  • Double-Blind Method
  • Follow-Up Studies
  • Humans
  • Mid-Atlantic Region / epidemiology
  • Placebos
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prospective Studies
  • Receptors, Prostaglandin / drug effects*
  • Receptors, Thromboxane
  • Recurrence
  • Sulfonamides / therapeutic use
  • Thromboxanes / antagonists & inhibitors*


  • Placebos
  • Platelet Aggregation Inhibitors
  • Receptors, Prostaglandin
  • Receptors, Thromboxane
  • Sulfonamides
  • Thromboxanes
  • sulotroban
  • Aspirin